Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) have received an average recommendation of “Hold” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $14.40.

CALA has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Friday, May 12th. Wells Fargo & Company reiterated an “outperform” rating and issued a $20.00 target price (up from $15.00) on shares of Calithera Biosciences in a report on Tuesday, June 6th. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price (up from $14.00) on shares of Calithera Biosciences in a report on Monday, June 12th. Finally, BidaskClub upgraded Calithera Biosciences from a “hold” rating to a “buy” rating in a report on Friday, July 7th.

In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $18.31, for a total value of $38,817.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 16.30% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP acquired a new position in Calithera Biosciences during the first quarter valued at $47,550,000. FMR LLC boosted its position in Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock valued at $40,349,000 after buying an additional 1,254,900 shares in the last quarter. State Street Corp boosted its position in Calithera Biosciences by 5,802.1% in the second quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock valued at $19,370,000 after buying an additional 1,282,275 shares in the last quarter. Vanguard Group Inc. boosted its position in Calithera Biosciences by 29.7% in the second quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock valued at $17,813,000 after buying an additional 274,510 shares in the last quarter. Finally, RA Capital Management LLC acquired a new position in Calithera Biosciences during the first quarter valued at $8,374,000. 55.11% of the stock is currently owned by institutional investors and hedge funds.

Calithera Biosciences (NASDAQ CALA) traded down 2.93% during trading on Tuesday, reaching $14.90. 155,186 shares of the company’s stock traded hands. Calithera Biosciences has a 12 month low of $2.20 and a 12 month high of $20.05. The firm’s 50 day moving average is $15.65 and its 200-day moving average is $13.26. The company’s market capitalization is $528.59 million.

Calithera Biosciences (NASDAQ:CALA) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.14. The business had revenue of $7.26 million during the quarter, compared to the consensus estimate of $4.80 million. Analysts expect that Calithera Biosciences will post ($0.83) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Calithera Biosciences, Inc. (CALA) Receives $14.40 Average Target Price from Analysts” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/25/calithera-biosciences-inc-cala-receives-14-40-average-target-price-from-analysts.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.